All In Biotech

NDA 216059 · Loxo Oncol

Jaypirca

Pirtobrutinib · Oral · Kinase Inhibitor

NovelAccelerated approvalPriority reviewOrphan

CDER novel approval, Jan 27, 2023: To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jan 27, 2023

Approved uses

4

Original approval plus efficacy supplements

Registered trials

81

10 Phase 3, 36 recruiting

FAERS reports

980

680 serious, 232 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 2, 2026.

JAYPIRCA ® is a kinase inhibitor indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. ( 1.1 ) This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. ( 1.2 ) Adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion. ( 1.3 ) 1.1 Mantle Cell Lymphoma JAYPIRCA ® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate [see Clinical Studies ( 14.1 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.2 Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. 1.3 Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma without 17p deletion JAYPIRCA is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p...

Mechanism: Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations, leading to inhibition of BTK kinase activity. In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell CD69 expression and inhibited malignant B-cell proliferation. Pirtobrutinib showed dose-dependent anti-tumor...

Therapeutic areas: Oncology · Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 2, 2026 Supplement 6 · Efficacy OrphanLabelLetter
  • Dec 2, 2025 Supplement 5 · Efficacy OrphanLabelLetter
  • Dec 1, 2023 Supplement 1 · Efficacy · priority review OrphanLabelLetter
  • Jan 27, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
2 products under this application
  • JAYPIRCA · PIRTOBRUTINIB 50MG · TABLET, ORAL · Prescription
  • JAYPIRCA · PIRTOBRUTINIB 100MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pirtobrutinib" as an intervention, any sponsor and status, largest first.

All 81 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death120
  • malignant neoplasm progression88
  • pneumonia74
  • off label use70
  • disease progression64
  • splenomegaly44
  • chronic lymphocytic leukaemia41
  • anaemia37
  • drug ineffective35
  • pancytopenia35
  • lymphadenopathy33
  • white blood cell count increased31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202217
2023117
2024173
2025286
2026387

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Jaypirca (Pirtobrutinib)

2024 spending

$201M

Beneficiaries

1,795

9,927 claims

Per beneficiary

$111,734

$355.85 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$49,251,883
2024$200,562,025

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 24 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.